$10.89
0.646.24%
Last update: 10:15 AM
15 minutes delayed
Neumora Therapeutics
NMRANASDAQ
want to know what
the Bulls & Bears Say?
Neumora Therapeutics (NASDAQ:NMRA) Stock, Analyst Ratings, Price Targets, Forecasts
Neumora Therapeutics Inc has a consensus price target of $19.86 based on the ratings of 11 analysis. The 3 most-recent analyst ratings were released by Mizuho, RBC Capital, and JP Morgan on July 8, 2024, March 28, 2024, and March 18, 2024, respectively. With an average price target of $24.33 between Mizuho, RBC Capital, and JP Morgan, there's an implied 123.45% upside for Neumora Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Mizuho
RBC Capital
JP Morgan
B of A Securities
William Blair
1calculated from analyst ratings
Analyst Ratings for Neumora Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 07/08/2024 | Buy Now | 83.65% | Mizuho | Graig Suvannavejh | → $20 | Initiates | → Outperform | Get Alert |
| 03/28/2024 | Buy Now | 184.66% | RBC Capital | Brian Abrahams | → $31 | Reiterates | Outperform → Outperform | Get Alert |
| 03/18/2024 | Buy Now | 102.02% | JP Morgan | Tessa Romero | $20 → $22 | Maintains | Overweight | Get Alert |
| 03/08/2024 | Buy Now | 184.66% | RBC Capital | Brian Abrahams | $24 → $31 | Maintains | Outperform | Get Alert |
| 11/08/2023 | Buy Now | 83.65% | JP Morgan | Tessa Romero | $21 → $20 | Maintains | Overweight | Get Alert |
| 10/10/2023 | Buy Now | 92.84% | JP Morgan | Tessa Romero | → $21 | Initiates | → Overweight | Get Alert |
| 10/10/2023 | Buy Now | 65.29% | B of A Securities | Geoff Meacham | → $18 | Initiates | → Buy | Get Alert |
| 10/10/2023 | Buy Now | — | William Blair | Myles Minter | — | Initiates | → Outperform | Get Alert |
| 10/10/2023 | Buy Now | 102.02% | Guggenheim | Yatin Suneja | → $22 | Initiates | → Buy | Get Alert |
| 10/10/2023 | Buy Now | 120.39% | RBC Capital | Brian Abrahams | → $24 | Initiates | → Outperform | Get Alert |
| 10/10/2023 | Buy Now | 138.75% | Stifel | Paul Matteis | → $26 | Initiates | → Buy | Get Alert |
FAQ
What is the target price for Neumora Therapeutics (NMRA) stock?
The latest price target for Neumora Therapeutics (NASDAQ:NMRA) was reported by Mizuho on July 8, 2024. The analyst firm set a price target for $20.00 expecting NMRA to rise to within 12 months (a possible 83.65% upside). 11 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Neumora Therapeutics (NMRA)?
The latest analyst rating for Neumora Therapeutics (NASDAQ:NMRA) was provided by Mizuho, and Neumora Therapeutics initiated their outperform rating.
When was the last upgrade for Neumora Therapeutics (NMRA)?
There is no last upgrade for Neumora Therapeutics
When was the last downgrade for Neumora Therapeutics (NMRA)?
There is no last downgrade for Neumora Therapeutics.
When is the next analyst rating going to be posted or updated for Neumora Therapeutics (NMRA)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Neumora Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Neumora Therapeutics was filed on July 8, 2024 so you should expect the next rating to be made available sometime around July 8, 2025.
Is the Analyst Rating Neumora Therapeutics (NMRA) correct?
While ratings are subjective and will change, the latest Neumora Therapeutics (NMRA) rating was a initiated with a price target of $0.00 to $20.00. The current price Neumora Therapeutics (NMRA) is trading at is $10.89, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.